Despite advances in preventive strategies, cytomegalovirus (CMV) infection remains a major
complication in solid organ and hematopoietic cell transplant recipients. CMV infection may …

Many advances have been made to optimize future clinical trials for management of
refractory or resistant CMV infections, and to better understand new resistance mechanisms …

A 9-month posttransplantation course of an allogeneic stem-cell transplant recipient (human
cytomegalovirus [HCMV] serostatus, donor positive/recipient negative), in whom ganciclovir …

Cytomegalovirus (CMV) remains a leading cause of morbidity after solid organ
transplantation. The efficiency of antivirals for the treatment of CMV infections may be …

The aim of this study was to characterize Human Cytomegalovirus (HCMV) drug resistance
mutations in UL97 and UL54 genes in allogeneic hematopoietic stem cell transplant (allo …

Antiviral-resistant cytomegalovirus infection remains a feared complication of transplantation
but is less frequently seen in AIDS patients in the current era. New research on resistance …

Drug‐resistant cytomegalovirus (CMV) should be considered when viral shedding persists
after several weeks of therapy. The problem is most likely to arise in the setting of a severely …

Four human cytomegalovirus (HCMV) isolates from four different AIDS patients treated with
both ganciclovir and foscarnet and not responding clinically to antiviral treatment, were …

Cytomegalovirus (CMV) infection is a significant complication in hematopoietic cell
transplantation (HCT) recipients. Four antiviral drugs are used for preventing or treating …

Background: Quantification of viral load in blood has proven to be helpful in the follow-up of
disseminated HCMV infections in immunocompromised patients. Objectives:(i) To describe …